The safety of pharmacotherapy of rheumatic diseases in gestation and lactation
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 6
Abstract
Rheumatic diseases frequently occur in young people, including women in the reproductive age. The problem of pregnancy is not a rare issue in this group. The decision about maintenance treatment or treatment of a flare of the disease occurring during pregnancy is always burdened with a high risk of maternal and foetal complications. The most commonly used nonsteroidal anti inflammatory drugs should be used in the lowest therapeutically sufficient dose and they should be stopped 8 weeks before the delivery. Among the glicocorticosteroids, prednisone and prednisolone have the safest profile as they are 90% metabolized in the placenta. Long-term, multicentre, retrospective studies have shown the relative safety of hydroxychloroquine, sulphasalazine and azathioprine, provided that they are used in the recommended doses under strict rheumatological and obstetrical supervision. Methotrexate, cyclophosphamide, mycophenolate mofetil and leflunomide are contraindicated in pregnancy. The reports on the safety of etanercept and infliximab during pregnancy are optimistic, however scanty. The use of cyclosporine should be limited due to increased risk of maternal and foetal complications. Low doses of nonsteroidal anti inflammatory drugs and prednisone do not exclude breastfeeding. -term, multicentre, retrospective studies have shown the relative safety of hydroxychloroquine, sulphasalazine and azathioprine, provided that they are used in the recommended doses under strict rheumatological and obstetrical supervision. Methotrexate, cyclophosphamide, mycophenolate mofetil and leflunomide are contraindicated in pregnancy. The reports on the safety of etanercept and infliximab during pregnancy are optimistic, however scanty. The use of cyclosporine should be limited due to increased risk of maternal and foetal complications. Low doses of nonsteroidal anti inflammatory drugs and prednisone do not exclude breastfeeding.
Authors and Affiliations
Lidia Ostanek, Danuta Bobrowska-Snarska, Marek Brzosko
Keywords
Related Articles
- EP ID EP118419
- DOI -
- Views 87
- Downloads 0
Von Willebrand disease haemostatic management and anesthesia for orthopedic surgery
We present the patient with type 1 von Willebrand (VWD) who underwent surgery for knee arthroscopy. We analysed the treatment options, the outcomes of haemostasis in the context of orthopedic surgery.
Czynniki predysponujące do wystąpienia zmian zapalnych i rozwoju niestabilności kręgosłupa szyjnego u chorych na reumatoidalne zapalenie stawów
Celem badania była ocena wybranych czynników predysponujących do wystąpienia zmian zapalnych i niestabilności górnego odcinka kręgosłupa szyjnego u chorych na reumatoidalne zapalenie stawów. W badaniu wzięło udział 100 c...
The presence of endotoxin in synovial fluids from connective tissue diseases (Ctd-s) patients with as a suspected disease aethiological marker
The aim of the study was to show the presence of endotoxin in the synovial fluids from the patients suffering of Ctd-s (in prevalence RA and other undifferentiated joint arthritis). The usefulness of the applied LAL-tes...
Evaluation of 12-lead resting ECG with QTc analysis in children with systemic and localized scleroderma
Scleroderma is chronic inflammatory disease of connective tissue of unknown etiology. Classification into two forms: systemic and localized scleroderma depends on type of skin symptoms, kind of immunological disturbances...
The Twentieth Congress of Russian Internists Centenary of the Russian Scientific Society of Internal Medicine Moscow, December 2-4, 2009